HMGB1 and Sepsis: In experimental murine models of endotoxemia [9] and sepsis, administration of anti-HMGB1 antibodies decreased mortality significantly [9,10], even when administration was delayed for 24 hours [10], providing a window for therapeutic intervention if transferred into a clinical setting.